Want to see HK:9996 full AI Analyst Report?
9996 Stock Chart & Stats
HK$6.51
-HK$0.07(-1.80%)
At close: 4:00 PM EST
HK$6.51
-HK$0.07(-1.80%)
Day’s Range― - ―
52-Week RangeHK$3.73 - HK$9.36
Previous CloseN/A
Volume6.00K
Average Volume (3M)1.88M
Market Cap
HK$2.71B
Enterprise ValueHK$2.21B
Total Cash (Recent Filing)HK$610.52M
Total Debt (Recent Filing)HK$434.22M
Price to Earnings (P/E)―
Beta1.23
Next Earnings
Aug 31, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.30
Shares Outstanding674,736,940
10 Day Avg. Volume1,295,000
30 Day Avg. Volume1,883,282
Financial Highlights & Ratios
PEG Ratio1.97
Price to Book (P/B)1.95
Price to Sales (P/S)5.04
P/FCF Ratio-11.04
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)<0.01
Revenue Forecast (FY)HK$897.68M
Bulls Say, Bears Say
Bulls Say
High Gross MarginsSustained ~67% gross margins indicate strong unit economics for catheter-based consumables. High product-level margins create durable room to fund R&D and commercialization, improving the company's ability to scale toward profitability as volumes and operational leverage increase.
Manageable LeverageLow debt-to-equity (~0.24) and sizable equity versus assets provide financial flexibility. This manageable leverage reduces refinancing and liquidity risk, allowing the company to sustain investment in market expansion and product development without immediate pressure to cut strategic spending.
Improving Loss/Cash TrajectoryCash burn and losses have narrowed versus prior years, and free cash flow improved versus 2023. A persistent improvement trend is a durable indicator management is executing scale and cost controls, lowering future external funding needs if the trajectory continues over coming quarters.
Bears Say
Persistent UnprofitabilityMaterial negative margins (net margin ~-29% in 2025) show the company still fails to convert sales into operating profits. Over months this constrains internal reinvestment, pressures returns, and keeps reliance on external capital until sustainable positive margins are achieved.
Weak Cash GenerationMeaningfully negative operating and free cash flow (about -325M in 2025) increases dependence on financing and raises dilution risk. Poor cash conversion limits ability to fund commercial rollouts, regulatory work, or R&D from operations, constraining durable growth options.
Negative Returns On EquityA negative ROE (~-11%) indicates the company is eroding shareholder equity rather than growing it. Persistently negative returns reduce internal capital for expansion, risk diluting economics through fundraising, and can weaken competitive positioning if not reversed over the medium term.
Peijia Medical Ltd. News
9996 FAQ
What was Peijia Medical Ltd.’s price range in the past 12 months?
Peijia Medical Ltd. lowest stock price was HK$3.73 and its highest was HK$9.36 in the past 12 months.
What is Peijia Medical Ltd.’s market cap?
Peijia Medical Ltd.’s market cap is HK$2.71B.
When is Peijia Medical Ltd.’s upcoming earnings report date?
Peijia Medical Ltd.’s upcoming earnings report date is Aug 31, 2026 which is in 28 days.
How were Peijia Medical Ltd.’s earnings last quarter?
Peijia Medical Ltd. released its earnings results on Mar 25, 2026. The company reported -HK$0.218 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$0.218.
Is Peijia Medical Ltd. overvalued?
According to Wall Street analysts Peijia Medical Ltd.’s price is currently Overvalued.
Does Peijia Medical Ltd. pay dividends?
Peijia Medical Ltd. does not currently pay dividends.
What is Peijia Medical Ltd.’s EPS estimate?
Peijia Medical Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Peijia Medical Ltd. have?
Peijia Medical Ltd. has 674,736,940 shares outstanding.
What happened to Peijia Medical Ltd.’s price movement after its last earnings report?
Peijia Medical Ltd. reported an EPS of -HK$0.218 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 1.792%.
Which hedge fund is a major shareholder of Peijia Medical Ltd.?
Currently, no hedge funds are holding shares in HK:9996
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Peijia Medical Ltd.
Peijia Medical Limited specializes in the innovation and development of advanced medical devices for transcatheter valve therapies and neurointerventional procedures. Their extensive portfolio of transcatheter valve solutions includes numerous TAVR (transcatheter aortic valve replacement) systems, such as TaurusOne, the retrievable TaurusElite, TaurusNXT (a non-glutaraldehyde dry-tissue system), TaurusApex (featuring polymer leaflets), and Trilogy. For mitral valve interventions, they offer the HighLife transseptal replacement system, SpyderOne (a transapical TMVR system), Sutra for coaptation augmentation, and the GeminiOne edge-to-edge repair system. They also provide the MonarQ and Peijia systems for transcatheter tricuspid valve replacement. Complementary devices supporting these procedures include the TaurusAtlas transfemoral balloon catheter, TaurusExplora pre-shaped guidewire, and introducer sheaths. In the neurointerventional field, Peijia Medical develops devices like the Jasper and Presgo detachable coils (including the Jasper SS variant), various intracranial adjunctive stents such as NeuroStellar, and the SacSpeed balloon dilatation catheter. Additional offerings comprise the Tethys AS aspiration catheter, Syphonet stent retriever, Neway balloon microcatheter, Fluxcap balloon guiding catheter, Presgo microcatheters and micro guidewires, Heralder guiding and distal access catheters, the Tethys intermediate catheter, and the Jasper power supply. Furthermore, the company engages in trading activities. Peijia Medical Limited was founded in 2012 and is headquartered in Suzhou, People's Republic of China.
Technical Analysis
MicroPort Scientific
―
LifeTech Scientific Corporation
―
AK Medical Holdings Ltd.
―
MicroPort CardioFlow Medtech Corp.
―
MicroPort NeuroTech Limited
―